Kornimate/medical-research-clean huggingface dataset:
multicenter study protocol: research on evaluation and detection of surgical wound complications with ai-based recognition. (redscar-trial)

Conditions: Surgical Wound Infection

Summary: the increasing use of telemedicine in surgical care has demonstrated significant poten-tial for improving patient outcomes and optimizing healthcare resources. this study investigates the efficacy of the redscar© app in telematic detection and monitoring of surgical site infections (ssis), a major cause of healthcare-associated infections (hais) with significant economic and health impacts. redscar© leverages a patient's smartphone to provide automated infection risk assessments without requiring clini-cian input, offering a potential solution for remote postoperative care. in a pilot study, redscar© demonstrated 100% sensitivity and 83.13% specificity in detecting ssis, with high patient satisfaction regarding its comfort, cost-effectiveness, and ability to reduce absenteeism. this multicenter prospective study aims to validate these findings, com-paring app-based detection with in-person evaluations. primary objectives include as-sessing the sensitivity and specificity of redscar© using receiver operating character-istic (roc) analysis, while secondary objectives include evaluating patient satisfaction and standardizing telematic follow-up across centers. the study will include 168 pa-tients undergoing abdominal surgery, with follow-up assessments conducted remotely via the app and in-person at specified intervals. data will be analysed using descrip-tive and statistical methods to assess diagnostic accuracy and patient satisfaction. this research seeks to further develop redscar© as a reliable, scalable tool for enhancing postoperative care, reducing healthcare costs, and improving patient experiences in surgical recovery.


Eligibility criteria:
inclusion criteria: * participants must have signed an informed consent. * participants must be over 18 years of age. * participants must have undergone either urgent or scheduled surgery performed via laparotomy or laparoscopy. * participants need access to a smartphone capable of downloading the app with android os. * either the participant or a close family member must be able to operate the app effectively. * participants must be able to attend follow-up consultations at the surgical outpatient clinic after discharge, one week post-surgery, or earlier if the app flags a potential infection. exclusion criteria: * patients who lack access to a smartphone or are unable to properly use the app. * patients unfamiliar with mobile devices or unable to comprehend the app's functionality or questions. * patients who did not provide informed consent. * patients who are unable to comply with the follow-up requirements.

Keywords: surgical wound infection telemedicine smartphone application artificial intelligence
remineralization effect of egg shell versus fluoride varnish on early carious white spot lesions in primary teeth

Conditions: White Spot Lesion

Summary: the goal of this clinical trial is to to assess the remineralization potential of egg shell hydrogel versus fluoride varnish in early carious white spot lesions in anterior primary teeth. the main question it aims to answer is:what is the remineralization potential of egg shell hydrogel on early carious white spot lesions compared to fluoride varnish in anterior primary teeth? researcher will compare egg shell hydrogel with fluoride varnish to see if it is able to promote lesion remineralization. interventions that will be given to participasnts: egg shell hydrogel \& five percent sodium fluoride varnish


Eligibility criteria:
inclusion criteria: 1. children aged 3 to 5 years, in good general health, and medically free. 2. prescence of at least one wsl on anterior primary teeth with an icdas ii score of one or two. 3. cooperative patients who will comply with follow-ups. 4. parents who accept to sign informed consent. exclusion criteria: 1. uncooperative children. 2. children with a physical disability or medical disability. 3. children with teeth that shows enamel hypoplasia. 4. children that have received a fluoride supplement or professional topical fluoride application at least 3 months before the study. 5. parents refuse to give written formed consent.
hd+ i-scan bronchoscopy vascular abnormalities detection multicenter study

Conditions: Lungcancer

Summary: videobronchoscopy is an essential diagnostic procedure for evaluation of the central airways and pivotal for the diagnosis and staging of lung cancer. further technological improvements have resulted in high definition (hd+) images and advanced image enhancement technique (i-scan). an earlier study (nct01676012) has indicated that hd+ bronchoscopy in combination with i-scan technology is superior to hd+wl (white light) for detecting endobronchial vascular changes. in this study we aim to correlate these vascular changes to histology and hypothesize that these vascular changes are related to (pre-) malignant changes and that the addition of i-scan is superior to hd+ wl.

patients will undergo a bronchoscopy with pentax eb1990i hd-bronchoscope in combination with pentax epki series videoprocessor investigating the entire bronchial tree. bronchoscopy will be performed by an experienced chest physician under local anaesthesia use and type of sedation following local protocol. bronchoscopy will be performed in a standardized order using three different imaging modes. the order of the different modes will be randomized to avoid induced scope and / or cough lesion bias. high definition digital videos will be made from all procedures without in screen patient identification, but using a study code. the three imaging modes used in this study are: hd+, hd+ surface enhancement (se, i-scan1) and hd+ surface enhancement and tone enhancement (te-c, i-scan2). when sites with abnormal or suspicious vascular patterns are detected the investigator grade these findings using a visual classification scale \[adapted from herth jto 2009 \& zaric med oncol 2013\] and change to a regular bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control. finally any other indicated procedures will be performed at the discretion of the local investigator.

Eligibility criteria:
inclusion criteria: * patients with indication for diagnostic bronchoscopy for suspected or proven lung cancer. * asa physical status 1-3. * age 18 years or older. * signed and dated patient informed consent. exclusion criteria: * bleeding disorders. * indication for use of anticoagulant therapy (acenocoumarol, warfarin, therapeutic dose of low molecular weight heparines or clopidrogel). * known allergy for lidocaine. * known pulmonary hypertension. * recent and/or uncontrolled cardiac disease. * compromised upper airway (eg concomitant head and neck cancer or central airway stenosis for any reason). * asa classification greater than or equal to 4. * pregnancy. * inability to consent.

Keywords: i-scan histology
bioequivalence study in patients with schizophrenia by using clozaril 100 mg tablet (clozapine) and wid-clz18

Conditions: Schizophrenia

Summary: this clinical study is a randomized, open label, multiple-dose, 2-way crossover, phase i (bioequivalence) study to compare the safety and pharmacokinetics profile of wid-clz18 and clozaril 100 mg tablet (clozapine) after oral administration in schizophrenia patients.


Eligibility criteria:
main inclusion criteria: 1. males and females adults aged 20 to 65 years 2. diagnosed as schizophrenia prior to the screening visit 3. on treatment with a stable dose of clozapine 200 mg/day for at least 12 weeks before the screening visit and taken at 100 mg twice daily during the study period main exclusion criteria: 1. subjects who have a medical history specified in protocol 2. subjects with confirmed abnormal laboratory values specified in protocol 3. subjects who have a medication history or safety risks specified in protocol 4. subjects who can not comply with requirements of pharmacokinetic sampling as per protocol 5. subjects who are expected to have the prohibited concomitant medication therapy during the study period 6. pregnant women or breast-feeding women or men and women who has possibility of pregnancy 7. subjects who are not suitable for the clinical trial
the development of a personalized decision aid: perspectives of patients and health care professionals on shared decision making and informational needs on radiotherapy for breast cancer

Conditions: Breast Cancer

Summary: background: the dutch guideline on breast cancer treatment shows several grey areas, where no clear recommendation is given on the radiotherapy options, but where the advice is to discuss the treatment of choice with the patient. currently, patients are exposed to different information given by the professionals' personal styles of informing patients. the challenge for all oncological professionals is to give clear, structured, and neutral information on the pros and cons of the treatment option(s) in the context of the natural course of the disease to the patient; to elicit patients' needs and preferences. how and which information should be shared in a decision aid is up for investigation, as well as how this should best be implemented. research goals: qualitative assessment of patients' and health care professionals' informational needs and perspectives on breast cancer radiotherapy and shard decision making. methods: semi-structured interviews will be held with both breast cancer patients and health care professionals. to reach as heterogeneous groups as possible patients of different ages, with different education levels and who underwent different treatments or chose not to get radiotherapy at all will be selected . data will be collected til saturation is reached. interviews will be transcribed verbatim and analysed using thematic analysis. results: results of the qualitative study are expected at the beginning of 2017. hypothesis: investigating the patients' and health care professionals' perspectives on shared decision making and informational needs on radiotherapeutic options will help the development of a personalized decision aid eligible for broad implementation.

semi-structured interviews with breast cancer patients and health care professionals.

Eligibility criteria:
inclusion criteria: * 2-3 months after facing decision or \> 1 year after decision * able to speak and understand dutch * written informed consent exclusion criteria: * recurrence of breast cancer prior to interview
antineoplaston therapy in treating patients with cancer of unknown primary origin

Conditions: Unknown Primary Carcinoma

Summary: current therapies for cancer of unknown primary origin provide very limited benefit to the patient. the anti-cancer properties of antineoplaston therapy suggest that it may prove beneficial in the treatment of cancer of unknown primary origin. purpose: this study is being performed to determine the effects (good and bad) that antineoplaston therapy has on patients with cancer of unknown primary origin.

cancer of unknown primary origin patients receive gradually escalating doses of intravenous antineoplaston therapy (atengenal + astugenal) until the maximum tolerated dose is reached. treatment continues up to 12 months in the absence of disease progression or unacceptable toxicity. objectives: * to determine the efficacy of antineoplaston therapy in patients with cancer of unknown primary origin, as measured by an objective response to therapy (complete response, partial response or stable disease). * to determine the safety and tolerance of antineoplaston therapy in patients with cancer of unknown primary origin. * to determine objective response, tumor size is measured utilizing mri scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter.

Eligibility criteria:
disease characteristics: * histologically confirmed adenocarcinoma of unknown primary that is unlikely to respond to existing therapy, including surgery, radiotherapy, and chemotherapy * evidence of tumor by mri, ct scan, chest x-ray, or radionuclide scan patient characteristics: age: * 6 months and over performance status: * karnofsky 60-100% life expectancy: * at least 2 months hematopoietic: * wbc at least 2,000/mm\^3 * platelet count at least 50,000/mm\^3 hepatic: * no hepatic insufficiency * bilirubin no greater than 2.5 mg/dl * sgot and sgpt no greater than 5 times upper limit of normal renal: * no renal insufficiency * creatinine no greater than 2.5 mg/dl * no history of renal conditions that contraindicate high dosages of sodium cardiovascular: * no uncontrolled hypertension * no history of congestive heart failure * no history of other cardiovascular conditions that contraindicate high dosages of sodium pulmonary: * no severe lung disease, such as chronic obstructive pulmonary disease other: * not pregnant or nursing * fertile patients must use effective contraception during and for 4 weeks after study participation * no active infection * no nonmalignant systemic disease * not a high medical or psychiatric risk prior concurrent therapy: biologic therapy: * at least 4 weeks since prior immunotherapy * no concurrent immunomodulating agents chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) endocrine therapy: * concurrent corticosteroids allowed radiotherapy: * at least 8 weeks since prior radiotherapy surgery: * recovered from prior surgery other: * prior cytodifferentiating agents allowed * no prior antineoplastons * no other concurrent antineoplastic agents
impact of genetic polymorphism on propofol requirement and recovery for total intravenous anesthesia for clipping of unruptured cerebral aneurysm in korean population

Conditions: Unruptured Cerebral Aneurysm

Summary: in neurosurgical anesthesia, propofol based total intravenous anesthesia (tiva) is frequently used due to brain relaxation and less effect on electrophysiologic monitoring. response to propofol can vary between individuals and be associated with clinical factors including age and weight, and genetic polymorphism. because the importance of rapid recovery in neurosurgery with long operation time is emphasized recently, the choice and dose adjustment of anesthetics should be determined according to clinical and genetic factors. recently, researches about genetic variations have been performed with single nucleotide polymorphism (snp). the aim of this study is to determine snps associated with propofol recovery and response in korean adult population undergoing propofol based tiva for clipping of unruptured cerebral aneurysm.


Eligibility criteria:
inclusion criteria: 1. korean adult population undergoing propofol based tiva for clipping of unruptured cerebral aneurysm exclusion criteria: 1. patients not able to read, or understand the consent form 2. ethnicity, other than korean population 3. patients refusal 4. patients not to perform total intravenous anesthesia

Keywords: propofol total intravenous anesthesia cerebral aneurysm single nucleotide polymorphism
impact of various sedation regimens on the incidence of delirium

Conditions: Delirium

Summary: sedation drugs that are commonly used in icu in treatment of ards, includes propofol, midazolam and dexmedetomidine . among these, both dexmedetomidine and propofol have been reported to be used together with midazolam in icu and the combination of propofol and midazolam is most commonly used, but things follow include a high incidence rate of delirium, but the combination of midazolam and dexmedetomidine may have complementary advantages and could have be a better choice for sedation. in this study, we attempted to observe the effects of two different drug regimens on delirium incidence rates in severe ards patients' : midazolam and propofol vs propofol and dexmedetomidine .


Eligibility criteria:
inclusion criteria: * subjects willing to give written informed consent. * mild, moderate or severe ards patients demanding invasive mechanical ventilation. * subjects whose expected time of mechanical ventilation is longer than 24 hours. * subjects aged between 18 and 70. exclusion criteria: * subjects with extremely unstable circulation, whose sbp lower than 90mmhg after volume expansion or pressor agent treatment. * subjects with extremely unstable circulation, whose sbp lower than 90mmhg after volume expansion or pressor agent treatment. * subjects with heart rates less than 50 beats per minute. * subjects with second or third degree atrioventricular block. * subjects with serious cerebral injury, severe neurologic disorder (e.g acute stroke, uncontrolled epilepsy and severe dementia) or coma. * subjects with acute or severe liver disease (child-pugh class c), see attachment 2. * ards patients caused by pulmonary fibrosis or copd. * subjects on all types hemodialysis. * subjects with neuromuscular system disease, alcohol withdrawal syndrome or mental disease before entrance of icu. * subjects suspected of narcotic analgesics abusing. * subjects needing neuromuscular blocking agents (except intubation). * subjects allergic to investigational products or with other contraindication. * subjects who are breastfeeding or pregnant * subjects participated in other study within 30 days before entrance of icu

Keywords: sedation; ards; mechanical ventilation hypnotics antianxiety drugs causing adverse effects therapeutic use
effect of hamstring stretching on cervical flexor muscle endurance

Conditions: Healthy

Summary: the superficial posterior line is one of the eight main fascial lines defined on the body. one of the important muscle groups on this line is the hamstring muscle group. studies have shown that various stretching methods applied to the hamstring muscle group affect the cervical region both in terms of range of motion and posture. as a result of this study, it was shown that deep neck flexor endurance increased in women who applied the pnf hold-relax method.

the superficial posterior line is one of the eight main fascial lines defined on the body. one of the important muscle groups on this line is the hamstring muscle group. studies have shown that various stretching methods applied to the hamstring muscle group affect the cervical region both in terms of range of motion and posture. our aim in our study is to examine the effect of the proprioceptive neuromuscular stretching (pnf) method applied to the hamstring muscle group on the endura of the deep neck flexors based on these data.

Eligibility criteria:
inclusion criteria: * being female * being healthy in musculoskeletal conditions exclusion criteria: * being hypermobile

Keywords: deep neck flexors hamstrings superficial back line proprioceptive neuromuscular stimulation
epo906 therapy in patients with advanced breast cancer

Conditions: Breast Neoplasms

Summary: this study will examine whether the investigational drug epo906, given by intravenous infusion (iv directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause breast cancer.


Eligibility criteria:
inclusion criteria: the following patients may be eligible for this study: * histologically or cytologically documented evidence of disease with at least one measurable lesion; * life expectancy of greater than three (3) months; * patients who have had only one prior therapy for metastatic disease; * patients who have received prior treatment with hormonal agents or who have had prior treatment regimens of radiotherapy in addition to one or no previous chemotherapy regimens are eligible; * patients who have had no prior therapy for metastatic disease, but who have received a taxane and an anthracycline (single or combination therapy) as adjuvant treatment, are eligible. for patients who have had previous radiation therapy to the target lesion(s), the lesion(s) must since have demonstrated progression. exclusion criteria: the following patients are not eligible for this study: * bone-only disease; * symptomatic pleural effusions; * symptomatic cns metastases or leptomeningeal involvement; * any peripheral neuropathy or unresolved diarrhea greater than grade 1; * severe cardiac insufficiency; * patients taking coumadin or other warfarin-containing agents with the exception of low dose coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports; * history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma ckin cancer or cervical cancer in situ; * active or suspected acute or chronic uncontrolled infection including abcesses or fistulae; * hiv+ patients; * pregnant or lactating females; * patients who have had radiation, chemotherapy, or hormonal therapy within the last four (4) weeks excluding palliative radiotherapy to isolated peripheral bone metastases not being used as markers for efficacy; * patients taking herceptin less than three (3) weeks prior to study start.

Keywords: breast cancer tumor tumour intravenous epothilone taxane anthracycline
human cns tau kinetics in tauopathies

Conditions: Progressive Supranuclear Palsy (PSP); Corticobasal Degeneration (CBD); Frontotemporal Dementia (FTD MAPT Mutation)

Summary: the goal of this study is to characterize tau kinetics and tau aggregation in the human cns and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies.

tauopathies are neurodegenerative diseases with tau pathology. these tauopathies are the most common pathology in neurodegenerative diseases, and they are reaching epidemic proportions. the rates of tau kinetics are central to understanding normal and abnormal processing and production and clearance of tau kinetics in humans to help understand the causes of tauopathy and evaluate tau-targeted therapeutics. this study will utilize the stable isotope labeling kinetics (silk) method to elucidate tau kinetics in vivo in the human central nervous system (cns) and its alteration in tauopathies. a total of \~34 participants from 3 different neurodegenerative diseases: frontotemporal dementia (ftd), corticobasal degeneration (cbd), and progressive supranuclear palsy (psp), will be invited to enroll in the study. participants will be labeled with stable isotopes via 16hr intravenous infusion and csf samples collected during subsequent lumbar puncture visits over \~120 days. csf will be analyzed over time for the quantitation of labeled tau.

Eligibility criteria:
inclusion criteria: * diagnosed with psp, cbd, or ftd mapt exclusion criteria: * clotting disorder * active anticoagulation therapy * active infection * meningitis * recent syncope * current experimental treatment targeting aβ or medications thought to influence aβ production or clearance rates (benzodiazepines, muscarinic agents, or anti-epileptics)

Keywords: tauopathies